INSTITUT GUSTAVE ROUSSY Patent applications |
Patent application number | Title | Published |
20150283228 | Recombinant Feline Leukemia Virus Vaccine Containing Optimized Feline Leukemia Virus Envelope Gene - The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions. | 10-08-2015 |
20150232932 | ANKRD26 AS A MARKER FOR DIAGNOSIS OF THROMBOCYTOPENIAS - An in vitro method for diagnosing thrombocytopenia in a subject, the method includes the step of assessing the ANKRD26 platelet expression in a biological sample from the subject, wherein a ANKRD26 platelet expression is indicative of a thrombocytopenia. Also described is a kit for diagnosing a thrombocytopenia in a subject, which includes at least one ANKRD26 nucleic acid probe or oligonucleotide or antibody for assessing the ANKRD26 platelet expression in a biological sample from the subject. | 08-20-2015 |
20150185202 | SIMULTANEOUS DETECTION OF CANNIBALISM AND SENESCENCE AS PROGNOSTIC MARKER FOR CANCER - The present inventors show that cannibal cells can undergo senescence after entosis in vivo and that the tumor suppressive protein p53 act as a repressor of this phenomenon. They therefore propose new tools to study the molecular pathways involved in the cannibalism process, for example by measuring the expression levels of p53 or splice variants thereof (such as Δ133TP53, TP53β, TP53γ or Δ40TP53), the release of extracellular ATP or purinergic P2Y2 receptor activity. The present inventors also demonstrated that the detection of senescent cannibal cells in breast adenocarcinoma obtained from patients treated with neo-adjuvant therapy positively correlates with good patient's response to treatment. Altogether, these results provide the first evidence that detection of cellular cannibalism and senescence simultaneously in tumors helps for the diagnosis of disease outcomes and for the prediction of treatment efficiency against cancer diseases. | 07-02-2015 |
20150133323 | METHOD FOR CHARACTERIZING CIRCULATING TUMOR CELLS, AND USE THEREOF IN DIAGNOSIS - Disclosed is a method for characterization, in a biological sample, of circulating tumour cells (CTCs) bearing at least one marker characteristic of the tumorous nature of the cell, the marker being selected from the groups constituted by: the oncogenic proteins characteristic of the CTCs, and the tumour markers. Also disclosed is the use of this method for deciding on the implementation of a treatment for a cancer patient. | 05-14-2015 |
20150105281 | Method for the Selection of Serum Biomarkers of Epigenetic Alterations, Particularly of Global Hypomethylation and Their Uses - The present invention provides a novel method for the selection of serum biomarkers of epigenetic alterations, particularly of global hypomethylation, and the use of said biomarkers in a method for screening, diagnosing and following a pathology associated to epigenetic alterations of cell in an individual, such as placental-related pathology or cancer. The present invention also relates to a method of detecting a predisposition to placental-related pathology or cancer based on the presence or the level of said biomarker in a serum or plasma sample of said patient. The present invention also relates to a method for predicting and following the effect of drugs targeting epigenetic modifications and in particular the effect of demethylating agents. The present invention is directed to a kit comprising such serum biomarkers of epigenetic alterations, particularly of global hypomethylation. | 04-16-2015 |
20150030623 | Recombinant Feline Leukemia Virus Vaccine Containing Optimized Feline Leukemia Virus Envelope Gene - The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions. | 01-29-2015 |
20140341857 | COMBINATION OF ONCOLYTIC ADENOVIRUSES WITH HISTONE DEACETYLASE INHIBITORS - The invention relates to the use of oncolytic adenoviruses with histone deacetylase inhibitors in combination therapy for cancer treatment. | 11-20-2014 |
20140329243 | METHOD FOR CHARACTERIZING CIRCULATING TUMOR CELLS, AND USE THEREOF IN DIAGNOSIS - Disclosed is a method for characterization, in a biological sample, of circulating tumour cells (CTCs) bearing at least one marker characteristic of the tumorous nature of the cell, the marker being selected from the groups constituted by: the oncogenic proteins characteristic of the CTCs, with the exception of the proteins encoded by the EML4-ALK fusion gene, and the tumour markers. Also disclosed is the use of this method for deciding on the implementation of a treatment for a cancer patient. | 11-06-2014 |
20140294880 | MUTATED LENTIVIRAL ENV PROTEINS AND THEIR USE AS DRUGS - A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier. | 10-02-2014 |
20140249204 | IDENTIFICATION OF A JAK2 MUTATION IN POLYCYTHEMIA VERA - The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group. | 09-04-2014 |
20130281313 | PROGNOSTIC AND/OR PREDICTIVE BIOMARKERS AND BIOLOGICAL APPLICATIONS THEREOF - The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to the identification of human genes and expression products thereof which can be used to assess the prognosis of a cancer in a subject, to assess the sensitivity of a subject to a treatment of cancer, or monitor, in particular determine the efficacy, of such a treatment of cancer after a given period of time. Said human genes and expression products can further be used (i) in the prevention or treatment of cancer, in particular to determine or select the appropriate cancer treatment for a given subject and/or for a particular tumor, as well as (ii) for the screening of therapeutically active drugs. Particular compounds capable to compensate, in a subject, an abnormal expression of one of the herein described products, in particular when the subject is exposed to a therapeutic treatment of cancer, thereby allowing or improving its efficiency in the subject, are also herein disclosed. Inventors, in addition, provide kits and DNA chips usable in the context of the present invention. | 10-24-2013 |
20130261088 | NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION - The present invention relates to novel derivatives of oxazaphosphorines that are pre-activated, to the methods for preparing same, to the pharmaceutical compositions containing same and to the therapeutic use thereof, in particular for treating cancer. | 10-03-2013 |
20130189683 | IDENTIFICATION OF A JAK2 MUTATION INVOLVED IN VAQUEZ POLYGLOBULIA - The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group. | 07-25-2013 |
20130164327 | Adenovirus vaccine vectors - The invention relates to recombinant adenovirus displaying one or more heterologous epitope(s) on their fiber protein. These recombinant adenovirus are useful as vaccines for generating an immune response against said epitope(s) in individuals having a pre-existing anti-Ad immunity. | 06-27-2013 |
20130156790 | COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT - The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumour. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumour to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition. It further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The present invention in addition provides kits, methods for selecting a compound of interest, as well as pharmaceutical compositions and uses thereof. | 06-20-2013 |
20130149323 | MUTATED LENTIVIRAL ENV PROTEINS AND THEIR USE AS DRUGS - A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier. | 06-13-2013 |
20130130928 | METHODS FOR PREDICTING OR MONITORING WHETHER A PATIENT AFFECTED BY A CANCER IS RESPONSIVE TO A TREATMENT WITH A MOLECULE OF THE TAXOID FAMILY - The present invention concerns in vitro methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family based on a resistance expression signature, kits for performing the methods, and methods for screening or identifying a compound suitable for improving the treatment of a cancer with a molecule of the taxoid family or for reducing the resistance development during the treatment of a cancer with the molecule of the taxoid family. | 05-23-2013 |
20130052160 | COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT - The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumour. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumour to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition. It further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The present invention in addition provides kits, methods for selecting a compound of interest, as well as pharmaceutical compositions and uses thereof. | 02-28-2013 |
20120302517 | TET2 AS A NEW DIAGNOSTIC AND PRONOSTIC MARKER IN HEMATOPOIETIC NEOPLASMS - The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour. | 11-29-2012 |
20120283132 | MOLECULAR IN VITRO DIAGNOSIS OF BREAST CANCER - A method for determining the benign or malignant state of a breast tumor in a biological sample is presented. The benign or malignant state is determined by measuring the variation of expression of twelve genes and at least one variant of each of the twelve genes when the variants exist, using a combination of 50 polynucleotide probe sets. An expression profile of the sample is then compared with reference expression profiles of control benign and malignant breast tissues. The probe sets can be arranged in a microarray. | 11-08-2012 |
20120252904 | MITF AS A MARKER FOR PREDISPOSITION TO CANCER - The present invention relates to a mutant of MITF which is useful as a marker for predisposition to the development of cancer and to uses thereof in diagnosis and preventive treatments, sumoylation being reduced or absent in this mutant. | 10-04-2012 |
20120189647 | POLYPEPTIDE SEQUENCE INVOLVED IN THE MODULATION OF THE IMMUNOSUPPRESIVE EFFECT OF VIRAL PROTEINS - Mutated viral ENV proteins having mutations in the immunosuppressive domain (ISU) of the transmembrane subunit (TM) have decreased immunosuppressive activity with respect to the wild-type ENV protein. Pharmaceutical compositions that include the protein and nucleic acids coding for the protein are also disclosed. | 07-26-2012 |
20120036587 | PROSTATE CANCER CELL LINES AND THEIR USE IN SCREENING METHOD - The present invention relates to a prostate cancer cell line CNCM deposit number I-4126, the use thereof for preparing resistant prostate cancer cell lines, the resistant prostate cancer cell lines, and the use of these prostate cancer cell lines for screening compounds of interest. | 02-09-2012 |
20120004136 | MSH2 AND ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN NON-SMALL-CELL LUNG CANCER - The invention is generally directed to a diagnostic method for predicting the benefit of the response of a subject diagnosed with cancer to a platinum compound-based adjuvant chemotherapy, preferably to a cisplatin-based chemotherapy which implements the determination of the MSH2 expression level in the biological sample containing tumor cells, and, optionally, the ERCC1 expression level. | 01-05-2012 |
20110263523 | TET2 AS A NEW DIAGNOSTIC AND PRONOSTIC MARKER IN HEMATOPOIETIC NEOPLASMS - The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour. | 10-27-2011 |
20110229411 | USE OF P2X7 PATHWAY FOR ASSESSING THE SENSITIVITY OF A SUBJECT TO A CANCER TREATMENT - The present invention concerns methods for assessing the sensibility of a subject to an anticancer treatment, for screening compounds which are useful for treating a cancer and for determining the likelihood of a metastatic relapse in a subject. The methods are based on the finding that a non-functional P2X7-elicited NALP3 inflammasome pathway in a subject is indicative of a resistance to treatment. The invention further concerns methods for treating a cancer and for restoring the sensitivity of the subject to a cancer treatment. | 09-22-2011 |
20110177970 | METHODS FOR PREDICTING OR MONITORING WHETHER A PATIENT AFFECTED BY A CANCER IS RESPONSIVE TO A TREATMENT WITH A MOLECULE OF THE TAXOID FAMILY - The present invention concerns in vitro methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family based on a resistance expression signature, kits for performing the methods, and methods for screening or identifying a compound suitable for improving the treatment of a cancer with a molecule of the taxoid family or for reducing the resistance development during the treatment of a cancer with the molecule of the taxoid family. | 07-21-2011 |
20110136685 | METHOD FOR DETERMINING A PREDISPOSITION TO BASAL CELL CARCINOMA AND FOR SCREENING TREATMENTS THEREOF - The present invention relates to methods for detecting a predisposition to a basal cell carcinoma and methods for screening a treatment of a basal cell carcinoma. | 06-09-2011 |
20110105365 | PRO-EPIL EXPRESSION LEVEL IN A BIOLOGICAL SAMPLE AS TESTICULAR CANCER BIOMARKER, PARTICULARLY IN COMBINATION WITH THE HCBETA AND AFP BIOMARKERS - The present invention is directed to the use of the expression level of the pro-EPIL gene as a biomarker for the diagnosing of testicular cancer, particularly a testicular germ cell tumor. The invention also relates to an in vitro method for detecting and/or classifying a testicular cancer in a subject comprising a step of determining the expression level of the gene encoding the pro-EPIL peptide in a biological, particularly in combination with the determination of the beta subunit HCGβ and the human alpha-fetoprotein AFP. The invention is also directed to a kit or solid support comprising nucleic acids or antibodies capable of determining the presence or the expression level of these three biological markers. | 05-05-2011 |
20110104136 | Natural Killer p30 (NKp30) Dysfunction and the Biological Applications Thereof - The present invention relates to a method of assessing a favourable or, on the contrary, an unfavourable prognosis of a cancer in the subject, which method comprises detecting the presence of a mutated Natural Cytotoxicity-triggering Receptor 3 (NCR3) nucleic acid, an abnormal relative amount of at least one particular Natural Killer p30 (NKp30) RNA transcript isoform, and/or an abnormal Natural Killer p30 (NKp30) expression or activity of at least one particular NKp30 protein isoform in a sample from the subject, the presence of said mutated NCR3 nucleic acid, abnormal relative amount of at least one particular NKp30 RNA transcript isoform, or abnormal expression or activity of at least one particular NKp30 protein isoform being indicative of the prognosis of said cancer in the subject. | 05-05-2011 |
20100266680 | Treatment of Cancer Using TLR3 Agonists - The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of a TLR3 receptor by cancer cells. | 10-21-2010 |
20100016235 | Inhibitors of Protein Phosphatase 1, GADD34 and Protein Phosphatase 1/GADD34 Complex, Preparation and Uses Thereof - The present invention relates to the use of a protein phosphatase inhibitor selected from an inhibitor of the catalytic subunit of the protein phosphatase 1 (PP1), an inhibitor of GADD34 and an inhibitor of the PP1/GADD34 complex to prepare a pharmaceutical composition to prevent or treat a cancer in a mammal, wherein the pharmaceutical composition is intended for administration in combination with a product used in a treatment of a cancer. | 01-21-2010 |
20100015653 | Compounds Regulating Calreticulin, KDEL Receptor and/or ERP-57 Cell Surface Exposure and Uses Thereof to Evaluate the Efficiency of a Cancer Treatment - The present invention relates to a method for determining the susceptibility of a patient tumour cell to a cancer treatment, which method comprises the detection or measure of CRT, KDEL receptor and/or ERp57 on the surface of a tumour cell. | 01-21-2010 |
20090280089 | Inhibition of the liver tropism of adenoviral vectors - The invention relates to the inhibition of liver tropism of adenoviral vectors, by replacement of the endogeneous HVR5 of hexon protein of said adenoviral vector with an heterologous polypeptide. | 11-12-2009 |
20090156531 | Use of Inhibitors of Scinderin and/or Ephrin-A1 for Treating Tumors - The invention relates to the use of inhibitors of the expression or the activity of scinderin and/or of ephrin-A1 inhibitors for increasing the susceptibility of tumor cells to CTL killing. Such inhibitors may be for instance interfering RNAs targeting the scinderin gene and/or interfering RNAs targeting the ephrin-A1 gene. | 06-18-2009 |
20080317811 | Treatment of Cancer Using Tlr3 Agonists - The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of TLR3 receptor by cancer cells. | 12-25-2008 |
20080253998 | TREATMENT OF CANCER USING TLR3 AGONISTS - The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of a TLR3 receptor by cancer cells. | 10-16-2008 |
20080220008 | Mutated Hiv Nef For Modulating Immunity - Described is the use of a mutation of at least one amino acid in the immunosuppressive domain of a HIV or SIV accessory protein, for modulating the immunosuppressive property of the protein. | 09-11-2008 |